• Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
  Fabbiani M, Gagliardini R, Ciccarelli N, et al  J Antimicrob Chemother. 2018 Apr 12

March  2018

• Long-term oral atazanavir attenuates myocardial infarction-induced cardiac fibrosis.
  Zhang G, Zhang X, Li D, Tian J, Jiang W. Eur J Pharmacol. 2018 Mar 29
• Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
  Imaz A, Niubó J, Amara A, et al  J Neurovirol. 2018 Mar 14
• FULL-TEXT ARTICLE
  Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
  Pilalas D, Skoura L, Margariti A, et alPLoS One. 2018 Mar 13;13(3):e0194262.
• Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort^.
  d'Arminio Monforte A, Lorenzini P,  et al  HIV Clin Trials. 2018 Mar 1:1-9.